Pargyline prevents MPTP-induced parkinsonism in primates
about
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryThe role of early life environmental risk factors in Parkinson disease: what is the evidence?Parkinson's Disease: The Mitochondria-Iron LinkIncreased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineMolecular mechanisms of neurotransmitter release.Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.Neurotoxicity of MPTP.Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases.Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+.The role of amine oxidases in xenobiotic metabolism.Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?Parkin disease and the Lewy body conundrumParkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.Mitochondrial dynamics in neurodegeneration.The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders.Environmental factors and Parkinson's disease: a case-control study in Belgrade, Serbia.Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B.Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP.The MPTP Story.Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases.Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons.Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations.Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP.Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+.Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues.Needs and opportunities for innovation in psychopharmacology.
P2860
Q24601233-233C88FF-43A5-4F50-9BDA-FB50DB233A9DQ24815642-6C76F649-2201-406C-9B79-0ACD2F1E98E5Q26746899-1BCCD4EE-DC6D-4241-8083-4C76979CFD66Q27308109-3CAE565B-89F3-46F5-BB56-56A930B84A62Q33191656-A44A3246-A1D4-49B6-A109-E800C2110007Q33641852-22E735E3-3382-45E1-92FC-2E84492FF361Q34228641-AC703AB4-69B9-4554-9E34-C18658A8D304Q34367534-74F2558C-6B0A-4E05-99DD-7F021A5F5B0BQ34523844-E3B4B732-4E1B-4573-AA0A-13E1A8EEADEEQ34597817-EAE23B60-1384-4697-A40F-FC66900AAFD1Q34625772-13E79B11-45DE-4473-B037-581CEE870B07Q34660052-5429DCAB-CECA-43B5-A519-180B12338A62Q36291772-C08D1CB3-7828-49FB-96D8-CA3B64899B5DQ36543104-EAE22E1E-98CE-4011-8FC7-08B0C2AA64D2Q36994301-13860950-3FFD-4816-8DC4-2C9B91D581F8Q37086050-4A6ADC46-89F0-49E0-8E4C-7F7C7EE5AF8FQ37683630-22C519B7-33A6-4CC5-B58C-B2F009D5D27EQ38060435-4118BB9F-C9F2-48AD-9F14-74FC21EF4F0EQ38198015-5636B9DF-D568-4B28-83EC-4229972F8570Q39929307-4A778FAE-5E7F-481A-9A92-4910DFCB11CFQ41484307-1786A8EE-0B71-465B-A1C5-2A697F98B822Q41817119-53418DEB-EE5B-4C2E-B197-8525FCBBE4DAQ41825283-F7B9622A-26E9-46BB-A750-2EBDBB50AE2DQ42574077-94C5B91A-60CF-4B1F-B84A-93C967F926B9Q42853435-B1FDB501-11A5-4733-8526-62B19C132AB7Q42854990-C1C91B8E-E688-402D-9246-A8CA7C051863Q43714311-588654E7-ED5F-4AA9-9BCA-DE5B251852B1Q44894528-98672AA6-0388-4D3F-A2A8-4E272C6C6EDAQ45099160-8001AD13-F41D-4F5B-B341-34027C0499F2Q45115174-F7723673-3756-4B5B-B6FA-B7E3EC56CA4CQ48452514-2EE82408-F32E-416C-969C-29B7254D878BQ48466606-C3636E2B-7614-48F8-A700-6386898BD705Q55618811-0D3B5F9F-DB5E-4CFC-9BB0-15A461A842D6
P2860
Pargyline prevents MPTP-induced parkinsonism in primates
description
1984 nî lūn-bûn
@nan
1984 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Pargyline prevents MPTP-induced parkinsonism in primates
@ast
Pargyline prevents MPTP-induced parkinsonism in primates
@en
Pargyline prevents MPTP-induced parkinsonism in primates
@nl
type
label
Pargyline prevents MPTP-induced parkinsonism in primates
@ast
Pargyline prevents MPTP-induced parkinsonism in primates
@en
Pargyline prevents MPTP-induced parkinsonism in primates
@nl
prefLabel
Pargyline prevents MPTP-induced parkinsonism in primates
@ast
Pargyline prevents MPTP-induced parkinsonism in primates
@en
Pargyline prevents MPTP-induced parkinsonism in primates
@nl
P2093
P3181
P356
P1433
P1476
Pargyline prevents MPTP-induced parkinsonism in primates
@en
P2093
E B Langston
J W Langston
P304
P3181
P356
10.1126/SCIENCE.6332378
P407
P577
1984-09-28T00:00:00Z